IDH2, an IDH (which convert isocitrate to α-KG), is frequently mutated in cancer, particularly in secondary glioblastoma [30], cytogenetically normal acute myeloid leukemia (AML) [31], cartilaginous tumors [32], and intrahepatic cholangiocarcinoma [33]. This evidence concerns the gene IDH2 and chondrogenic neoplasm.